Dr. Falk Pharma GmbH
Dr. Falk Pharma is a research-based family business with a focus on developing and distributing innovative medicines in digestive and metabolic medicine. With over 60 years of experience, the company aims to improve patients' health and well-being through effective therapies, especially for inflammatory bowel disease and related conditions. The company emphasizes innovation, scientific dialogue, and global presence, with a commitment to therapeutic progress and patient safety.
Industries
Nr. of Employees
medium (51-250)
Dr. Falk Pharma GmbH
Leinenweberstr. 5, 79108 Freiburg, Germany
Patents
Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
US-11738032-B2
View DetailsOptimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
US-11382860-B2
View Details
Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
US-11738032-B2
View DetailsOptimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
US-11382860-B2
View DetailsProducts
Therapeutic portfolio for digestive and metabolic diseases
A portfolio of medicinal therapies indicated for gastrointestinal and hepatobiliary conditions including inflammatory bowel disease, eosinophilic esophagitis, chronic constipation and cholestatic liver diseases.
Therapeutic portfolio for digestive and metabolic diseases
A portfolio of medicinal therapies indicated for gastrointestinal and hepatobiliary conditions including inflammatory bowel disease, eosinophilic esophagitis, chronic constipation and cholestatic liver diseases.
Services
Offers collaboration, licensing and acquisition opportunities across discovery, clinical development, regulatory, manufacturing and commercialization.
Maintains channels for intake of suspected side effects and product quality reports for marketed medicinal products.
Organizes symposia, workshops and conferences with CME credits, covering topics in mucosal immunology, hepatology and other clinical areas.
Implements and advises on serialization, aggregation and tamper‑evident packaging to meet anti‑counterfeit regulations.
Produces disease‑specific brochures and on‑demand educational content for patients and healthcare professionals.
Provides clinical development activities including trial initiation, enrollment management and trial reporting.
Offers collaboration, licensing and acquisition opportunities across discovery, clinical development, regulatory, manufacturing and commercialization.
Maintains channels for intake of suspected side effects and product quality reports for marketed medicinal products.
Organizes symposia, workshops and conferences with CME credits, covering topics in mucosal immunology, hepatology and other clinical areas.
Implements and advises on serialization, aggregation and tamper‑evident packaging to meet anti‑counterfeit regulations.
Produces disease‑specific brochures and on‑demand educational content for patients and healthcare professionals.
Provides clinical development activities including trial initiation, enrollment management and trial reporting.
Expertise Areas
- Gastroenterology and hepatology
- Inflammatory bowel disease (IBD)
- Eosinophilic esophagitis (EoE)
- Primary biliary cholangitis and cholestatic liver diseases
Key Technologies
- Phase II/III clinical trial methodologies
- Regulatory filing processes (IND/IDE)
- Serialization and track‑and‑trace systems
- Tamper‑evident packaging
News & Updates
Evaluating Naronapride in Gastroparesis (MOVE-IT)
IBD Has No Borders – Breaking Taboos, Talking About It.
Help to raise awareness on May 22, 2025!
The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.
Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.
Did you know that our first product back in 1960 was a therapeutic drug for the liver?
Evaluating Naronapride in Gastroparesis (MOVE-IT)
IBD Has No Borders – Breaking Taboos, Talking About It.
Help to raise awareness on May 22, 2025!
The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.
Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.
Did you know that our first product back in 1960 was a therapeutic drug for the liver?